Why Is MoonLake Immunotherapeutics Stock Trading Higher Today?

On Sunday, MoonLake Immunotherapeutics MLTX announced that continued treatment with Nanobody sonelokimab led to significant improvements across all key outcomes at 24-week data from the ARGO trial in psoriatic arthritis (PsA). The 207-patient ARGO trial demonstrated that the primary endpoint, the…#pasi #abbvieincs #abbvhumira #acr50pasi100 #acr #mda #tnf #moonlake
Source: Reuters: Health - Category: Consumer Health News Source Type: news